Molecular Pharmacology (MLPH) 8-K New International Patent Applications Filed Over Expanded Biological Activity Profiles

Exhibit 99.3

		Molecular Pharmacology (USA) Limited
Zn-plasma protein complex reduces cytokine production in LPS-stimulated monocytes
Anthea Downs*,  Prue Hart#, John Snowden*, Chris Quirk*Maud Eikenboom* *Molecular Pharmacology Limited (USA), Australian division, Perth, Western Australia #Telethon Institute for Child Health Research, Perth, Western Australia
INTRODUCTION MPL is developing a biologically active anti-inflammatory agent, derived from fractionated bovine plasma proteins conjugated with zinc (Bov-Zn). Here, the ability of the proprietary Bov-Zn to regulate cytokine production by LPS-stimulated monocytes is assessed (exp.1). The results were validated by competitive inhibition studies between Bov-Zn and fetal calf serum (exp.2), and by assessment of the effect of Bov-Zn on monocyte metabolism (exp.3).			Table Excluded
METHOD For all experiments, human monocytes were cultured in RPMI/10% FCS at 37oC/5%CO2. Exp 1: Human monocyte cultures were stimulated with 500ng/ml LPS (E.coli 0111:B4) in the presence of 0%, 2.5%, 5%, 7.5%, 10%, 20% or 40% Bov-Zn. After 24 hrs incubation, culture media were collected, centrifuged, and assayed (TNF-α ELISA). Exp.2: A competitive inhibition design was set up using 0%, 1%, 5%, 10% FCS against 0%, 2.5%, 5%, 10% Bov-Zn. Exp.3: Metabolism of non-proliferating monocytes was measured via accumulation of bioreduced formazan (Promega CellTiter 96) in treated and untreated cell cultures				Fig 1: Efficacy (%) of Bov-Zn in suppressing LPS LPSstimulated human monocyte TNF-α measured in supernatant after incubation with 0, 2.5, 5, 7.5, 10, 20, or 40% Bov-Zn for 24hrs.
			Table Excluded
RESULTS The IC50 for suppression of LPS-stimulated human monocyte TNF-α production was reached at 2.5% Bov-Zn (Fig.1). FCS did not compete with Bov-Zn in suppressing TNF-α in LPS-stimulated monocytes. At low FCS concentrations Bov-Zn stimulated TNF-α production in the absence of LPS (p<0.05). This increase in TNF-α was countered with increasing concentrations of FCS (Fig.2, Treat x Dose: p<0.01). Cellular metabolism was not affected by 10% Bov-Zn (Fig. 3, Time x Treat: F7,28 = 0.96, n.s.; Treat: F1,28 = 0.13, n.s ).			Fig. 2: Suppression of LPS-stimulated human monocyte TNF-α secretion in a competitive inhibition design for 0, 1, 5, 10% FCS against 0, 2.5, 5, 10% Bov-Zn.
Table Excluded	Fig. 3: Absorbance of formazan at 450nm, reflecting cell metabolism, of human monocytes incubated with 0% or 10% Bov-Zn. Triplicate samples were taken at 0, 1, 2, 3, 4, 5, 21 and 45hrs incubation.		CONCLUSION Bov-Zn reduces LPS-stimulated human monocyte TNF-α secretion in vitro, without competing with FCS in the culture medium, and without disturbing the metabolism of monocytes.